cell therapy and a subsidiary of Gilead Science, Inc. He severed as Chief Medical Officer of Cell Design Labs, Inc., a biotechnology company developing cell-based therapies, from 2017 to 2018. Previously, Dr. Sidhu served in various roles of increasing responsibility, including Global Product General Manager of Translational Sciences of Amgen, Inc., a biopharmaceutical company, from 2016 to 2017. Dr. Sidhu received an M.D. from Queen’s University and a B.Sc. in Biochemistry from the University of Alberta.
Director Nominees
Charles Cherington, Chairman, has served on our Board of Directors since March 2021. Prior to that, Mr. Cherington served on our board of managers from 2018 through 2021. Mr. Cherington is a Co-Founder and Managing Partner of Ara Partners, a global private equity firm focused on industrial decarbonization investments founded in 2017. Previously, Mr. Cherington co-founded and served as Managing Partner of Intervale Capital, a middle-market private equity firm focused on investments in energy and infrastructure sectors, from 2006 to 2017. Mr. Cherington was Founder and Sole Partner of Cherington Capital, a private equity firm, from 2002 to 2006. In 1999, Mr. Cherington co-founded Paratus Capital Management, LLC, a venture capital firm, where he served as Partner until 2004. Prior to 1999, Mr. Cherington served in various positions with Lochridge & Company, Inc., a business management consulting firm, and as an investment banker for Credit Suisse First Boston. Mr. Cherington received a B.A. in History from Wesleyan University and an M.B.A. from the University of Chicago.
Mr. Cherington’s qualifications to serve on our Board of Directors include his extensive experience and senior management roles in companies in the life sciences and private equity industries, and his business training and education.
Erin S. Enright, J.D., has served on our Board of Directors since January 2022. Ms. Enright has served as a Managing Member of Prettybrook Partners, LLC, a family office dedicated to investing in healthcare companies, since 2012. She previously served as President and owner of Lee Medical Corporation, a medical device manufacturer, from 2004 to 2013 and as Chief Financial Officer of InfuSystem Holdings, Inc., a provider of infusion pumps and related services, from 2005 to 2007. From 1993 to 2003 Ms. Enright was with Citigroup, where she was a Managing Director in its Equity Capital Markets group. Ms. Enright is a director, the Chairman, the Chair of the Nominating and Governance Committee, and a member of the Audit and Compensation Committees of Dynatronics Corporation (NASDAQ: DYNT), a medical device company, and a director, the Chair of the Investment Committee and a member of the Audit Committee of Medical Facilities Corporation (TSX: DR), owner of a diverse portfolio of surgical facilities in the United States. Ms. Enright received an A.B. in Public and International Affairs from the School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School.
Ms. Enright’s qualifications to serve on our Board of Directors include her extensive background in various roles within the life sciences industry, which has provided her with capital markets, corporate governance, finance, legal and public company board experience.
Howard Federoff, M.D., Ph.D., has served as Chief Executive Officer, President and one of our directors since April 2021. Prior to that, Dr. Federoff served as senior adviser from January 2021 to April 2021 and as chief executive officer from August 2019 to December 2020 at Aspen Neuroscience, Inc., a biotechnology company developing an autologous neuron replacement program for Parkinson’s disease. He is a former Professor of Neurology at the University of California, Irvine, School of Medicine from 2015 to April 2021. Dr. Federoff also served as Vice Chancellor for Health Affairs and Chief Executive Officer of the UC Irvine Health System from 2016 to 2018 and as Vice Chancellor for Health Affairs and Interim Chief Executive Officer of the UC Irvine Health System and as Dean of the University of California, Irvine, School of Medicine from 2015 to 2016. From 2007 to 2015 he was Executive Vice President for Health Sciences and Executive Dean of the School of Medicine at Georgetown University. Dr. Federoff has chaired the Recombinant DNA Advisory Committee of the National Institute of Health, the National Heart, Lung and Blood Institute Gene Therapy Resource Group, and the Board of the Association of Academic Health Centers. Dr. Federoff is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Investors. Dr. Federoff received a Ph.D. in Biochemistry and an M.D. from Albert Einstein College of Medicine of Yeshiva University.
Dr. Federoff’s qualifications to serve on our Board of Directors include his experience in the healthcare industry, his business training and education, and his experience serving on multiple boards over the course of his career.
Dennis H. Langer, M.D., J.D., has served on our Board of Directors since May 2021. Dr. Langer has served as director of several public and private health care companies, and served in leadership roles in several pharmaceutical,